Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 4 of 25
  1. NUC01, Placebo to NUC01

    Dr. Falk Pharma GmbH

    primary sclerosing cholangitis (PSC)

    phase 3 small molecule active

    1 trial
  2. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial
  3. NiuBangZi pill or NiuBangZi pill placebo

    Universal Integrated

    Niu Bang Zi Pill

    phase 3 small molecule active

    1 trial
  4. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial
  5. Olpasiran, Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial
  6. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial
  7. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial
  8. PLACEBO for amyotrophic lateral sclerosis

    Istituto Gentili S.r.l.

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial
  9. PRIDOPIDINE, Pridopidine placebo

    Ferrer Internacional S.A.

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial
  10. Placebo

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 mab completed

    1 trial
  11. Placebo

    Sanofi Pasteur

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial
  12. Placebo

    AbbVie

    Psoriatic Arthritis

    phase 3 mab active

    1 trial
  13. Placebo

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial
  14. Placebo

    Takeda

    Lennox Gastaut Syndrome (LGS)

    phase 3 small molecule completed

    1 trial
  15. Placebo

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials
  16. Placebo

    AstraZeneca

    Irritable Bowel Syndrome With Constipation (IBS-C)

    phase 3 small molecule completed

    1 trial
  17. Placebo

    Tobira Therapeutics

    Nonalcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial
  18. Placebo

    Novartis Pharmaceuticals

    IC-MPGN

    phase 3 small molecule active

    1 trial
  19. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Erectile Dysfunction

    phase 3 small molecule completed

    1 trial
  20. Placebo

    Allergan Pharmaceuticals International Limited

    Gastroparesis

    phase 3 small molecule terminated

    3 trials
  21. Placebo

    Takeda

    Male Subjects With Chronic Constipation

    phase 3 small molecule completed

    1 trial
  22. Placebo

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule completed

    1 trial
  23. Placebo

    Eli Lilly and Company

    Hepatocellular Carcinoma

    phase 3 mab completed

    1 trial
  24. Placebo

    Ono Pharmaceutical Co.,

    Chronic Sinusitis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.